New low-dose liquid pilocarpine formulation for treating dry mouth in Sjögren’s syndrome: clinical efficacy, symptom relief, and improvement in quality of life

Table 4 Effect on daily activities following administration of pilocarpine solution to patients with Sjӧgren’s syndrome

Item	VAS (5 cm) ^a
Item	Pre-administration	Continuous administration
General activities (n = 21)	2.4 (1.2, 3.3)	1.0 (0.3, 2.0)**
Normal work (n = 21)	2.4 (1.0, 3.4)	1.0 (0.4, 2.1)
Interpersonal relationships (n = 20)	2.4 (1.5, 3.2)	1.4 (0.7, 2.4)**
Food intake (n = 18)	2.6 (1.0, 4.0)	1.4 (0.7, 3.0)*
Sleep (n = 20)	2.4 (0.8, 2.7)	1.5 (0.7, 2.5)
Appetite (n = 20)	0.9 (0.6, 2.4)	1.1 (0.5, 1.7)

*: Significantly different from pre-administration at P < 0.05; **: P < 0.01 (Wilcoxon signed-rank test)
^aVAS, visual analog scale; Median (1st quartile, 3rd quartile)

ISSN: 2055-0294